Core Viewpoint - A class action lawsuit has been filed against Alexandria Real Estate Equities, Inc. for alleged violations of federal securities laws during the specified class period [1][2]. Group 1: Lawsuit Details - The lawsuit seeks to recover damages for investors who purchased Alexandria securities between January 27, 2025, and October 27, 2025 [2]. - The Complaint alleges that the defendants made materially false and misleading statements regarding the company's Long Island City property and its leasing value as a life-science destination [3]. - It is claimed that the defendants concealed material adverse facts and that their statements about the company's business and prospects were misleading [3]. Group 2: Next Steps for Investors - Investors who suffered losses in Alexandria have until January 26, 2026, to request to be appointed as lead plaintiff in the case [4]. - A copy of the Complaint can be reviewed on the law firm's website [4]. Group 3: Legal Representation - The law firm represents investors on a contingency fee basis, meaning they will only collect fees if the case is successful [5]. - Bronstein, Gewirtz & Grossman, LLC is recognized for recovering significant amounts for investors in securities fraud cases [6].

Core Points - Rosen Law Firm is reminding purchasers of MoonLake Immunotherapeutics common stock about the December 15, 2025 lead plaintiff deadline for a class action lawsuit [1][3] - Investors who purchased shares during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] Company Details - The complaint alleges that during the Class Period, defendants made false and misleading statements regarding the efficacy of SLK compared to traditional monoclonal antibodies, specifically concerning the molecular targets and clinical benefits [5] - The lawsuit claims that when the true details were revealed, investors suffered damages due to the misleading information provided by the defendants [5] Legal Process - To join the class action, investors can submit a form or contact the law firm directly for more information [3][6] - It is noted that no class has been certified yet, and investors are not represented by counsel unless they retain one [7]

Core Viewpoint - Baxter International Inc. is facing a class action lawsuit due to allegations of misleading statements regarding the safety and efficacy of its Novum LVP product, which reportedly suffered systemic defects leading to serious patient risks [6][8]. Group 1: Legal Proceedings - Faruqi & Faruqi, LLP is investigating potential claims against Baxter and has set a deadline of December 15, 2025, for investors to seek the role of lead plaintiff in the class action lawsuit [3]. - The lawsuit claims that Baxter and its executives violated federal securities laws by failing to disclose critical information about the Novum LVP's defects and the associated risks to patients [6]. Group 2: Product Issues - The Novum LVP was reported to have systemic defects causing malfunctions such as underinfusion, overinfusion, and complete non-delivery of fluids, which posed serious risks to patients [6]. - Baxter was allegedly aware of multiple device malfunctions, injuries, and deaths related to these defects but did not take adequate remedial measures [6]. Group 3: Market Impact - Following the announcement on July 31, 2025, regarding the voluntary pause of shipments and installations of the Novum LVP, Baxter's stock price fell by 22.4%, closing at $21.76 [8].

Core Viewpoint - A class action lawsuit has been filed against Freeport-McMoRan Inc. and certain senior executives for securities fraud, following significant stock drops attributed to potential violations of federal securities laws [1][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the District of Arizona, captioned Reed v. Freeport-McMoRan Inc., et al., No. 2:25-cv-04243 [3]. - Investors have until January 12, 2026, to request to be appointed to lead the case [3]. - The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Freeport securities [3]. Group 2: Company Operations and Safety Claims - Freeport-McMoRan operates the Grasberg Copper and Gold Mine in Indonesia through its affiliate PT Freeport Indonesia [4]. - The company previously emphasized its commitment to safety, claiming to utilize data, technology, and behavioral science to prevent fatal incidents [4]. - Allegations suggest that Freeport overstated its safety commitment, as unsafe mining practices were conducted at the Grasberg mine, likely leading to worker fatalities [5]. Group 3: Stock Price Impact - On September 9, 2025, Freeport's stock dropped by $2.77 per share (over 5.9%) following a press release about suspended mining operations due to a landslide [6]. - On September 24, 2025, after an update on the incident revealing two fatalities and five missing team members, the stock fell by $7.69 per share (almost 17%) [7]. - A report on September 25, 2025, regarding strained relations with the Indonesian government led to an additional drop of $2.33 per share (over 6%) [8]. - An Indonesian news report on September 28, 2025, indicated that the landslide was preventable, further impacting investor sentiment [9].

Core Viewpoint - A class action lawsuit has been filed against Inspire Medical Systems, Inc. and certain senior executives for securities fraud following a significant stock drop due to alleged violations of federal securities laws [1][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the District of Minnesota, specifically titled City of Pontiac Reestablished General Employees' Retirement System v. Inspire Medical Systems, Inc., et al., No. 0:25-cv-04247 [3]. - Investors have until January 5, 2026, to request to be appointed to lead the case [3]. Group 2: Company Background - Inspire Medical Systems develops and manufactures an implantable medical device for treating sleep apnea, with the latest version being Inspire V, which received FDA approval on August 2, 2024 [4]. Group 3: Stock Performance and Issues - Inspire assured investors that it had taken necessary steps for the launch of Inspire V, claiming high demand would support the rollout [5]. - Contrary to these assurances, the company allegedly failed to prepare clinicians and payors adequately, leading to significant delays and weak demand due to excess inventory of older devices [6]. - On August 4, 2025, Inspire disclosed an "elongated timeframe" for the Inspire V launch and reduced its 2025 earnings per share guidance by over 80% [7]. - Following this announcement, Inspire's stock price fell by $42.04, or more than 32%, from $129.95 on August 4, 2025, to $87.91 on August 5, 2025 [8].

Core Viewpoint - A class action lawsuit has been filed against Stride, Inc. for securities fraud, alleging significant stock drops due to potential violations of federal securities laws [1][2]. Company Overview - Stride, Inc. is an education technology company that provides an online platform for students across the U.S. [3]. Allegations - The lawsuit claims that Stride inflated enrollment numbers by retaining "ghost students," ignored compliance requirements, and had a poor customer experience leading to higher withdrawal rates and lower conversion rates [3][4]. Stock Performance - On September 14, 2025, a report of fraud allegations caused Stride's stock to drop by $18.60, or over 11%, from $158.36 to $139.76 per share [4]. - Following Stride's admission of poor customer experience on October 28, 2025, the stock plummeted by $83.48, or more than 54%, from $153.53 to $70.05 per share [5]. Legal Proceedings - Investors have until January 12, 2026, to request to lead the case in the U.S. District Court for the Eastern District of Virginia [2]. - The lawsuit is captioned MacMahon v. Stride, Inc., et al., No. 1:25-cv-02019 [2]. Impact on Business - Stride estimated a loss of approximately 10,000-15,000 enrollments due to the issues raised, leading to a muted outlook compared to previous years [5].

Core Viewpoint - A class action lawsuit has been filed against Synopsys, Inc. and certain senior executives for securities fraud following a significant stock drop due to potential violations of federal securities laws [1][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Northern District of California, captioned Kim v. Synopsys, Inc., et al., No. 3:25-cv-09410 [3]. - Investors have until December 30, 2025, to request to be appointed to lead the case [3]. Group 2: Company Performance - Synopsys provides design automation software products, with its Design IP segment being the fastest-growing, increasing from 25% of revenue in 2022 to 31% in 2024 [4]. - In Q3 2025, Synopsys reported a revenue of $425.9 million for its Design IP segment, reflecting a 7.7% year-over-year decline, and a net income of $242.5 million, a 43% year-over-year decline [6]. Group 3: Market Reaction - Following the release of disappointing Q3 2025 results, Synopsys stock fell from $604.37 per share to $387.78 per share, a decline of nearly 36% [6].

Core Viewpoint - A lawsuit has been filed against MoonLake Immunotherapeutics and its senior executives for potential violations of federal securities laws, following disappointing results from its Phase 3 VELA trials for sonelokimab [1][2][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Southern District of New York, captioned Peters v. MoonLake Immunotherapeutics, et al., No. 1:25-cv-08612 [2]. - Investors have until December 15, 2025, to request to be appointed to lead the case [2]. Group 2: Company Background - MoonLake is a clinical-stage biotechnology company focused on developing therapies for inflammatory diseases, specifically targeting moderate to severe hidradenitis suppurativa with its investigational drug sonelokimab [3]. Group 3: Clinical Trials and Allegations - MoonLake claimed that its "strong clinical data" from the Phase 2 MIRA trial indicated superior clinical responses for patients, suggesting a competitive advantage for sonelokimab [4]. - Allegations state that the clinical data and Nanobody structure did not provide a superior clinical benefit compared to competitors, raising doubts about the drug's regulatory approval and commercial viability [5]. Group 4: Stock Performance - Following the announcement of disappointing results from the VELA Phase 3 trials on September 28, 2025, MoonLake's stock price plummeted nearly 90%, from $61.99 per share to $6.24 per share [6].

Core Viewpoint - An investigation has been announced regarding Baidu, Inc. for potential violations of federal securities laws, which may impact investors who have incurred losses [1] Company Investigation - The Law Offices of Frank R. Cruz is leading the investigation on behalf of investors [1] - The investigation is prompted by a report from Reuters dated November 26, 2025, referencing a letter from the Deputy Defense [1]

Accessibility StatementSkip Navigation BENSALEM, Pa., Nov. 26, 2025 /PRNewswire/ -- The Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Primo Brands Corporation ("Primo Brands" or the "Company") (NYSE:Â PRMB). IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN PRIMO BRANDS CORPORATION (PRMB), CONTACT THE LAW OFFICES OF HOWARD G. SMITHÂ BEFORE JANUARY 12, 2026 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE ...